<List><item><source>MED</source><extId>29651445</extId><pmcid>PMC5831954</pmcid><annotations><annotation><prefix>for refractory renal cell carcinoma (</prefix><exact>NCT00422786</exact><postfix>). </postfix><tags><tag><name>NCT00422786</name><uri>http://identifiers.org/clinicaltrials/NCT00422786</uri></tag></tags><id>http://europepmc.org/articles/PMC5831954#europepmc-a73eae55a35b603b7141a69780898fdd</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>e 2 clinical trial (</prefix><exact>NCT00713518</exact><postfix>) for the treatment </postfix><tags><tag><name>NCT00713518</name><uri>http://identifiers.org/clinicaltrials/NCT00713518</uri></tag></tags><id>http://europepmc.org/articles/PMC5831954#europepmc-e3ab80d0131e025bb21d75af2d9df11d</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>